

Supplementary Material

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”

Authors: Timothy E. Albertson,¹ Caitlin Hansen,² Juleen Gayed,³ Xia Xu,⁴ Ye Feng,² and Hua Ma⁴

Affiliations: ¹UC Davis Medical Center, Sacramento, CA, USA; ²Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA; ³Vaccine Research and Development, Pfizer Ltd, Marlow, UK; ⁴Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA

Corresponding author

Juleen Gayed, MBBS, MSc, FFPM *Corresponding author*
Vaccine Clinical Research & Development, Pfizer Ltd
juleen.gayed@pfizer.com

Supplementary Table 1. Percentages of participants by troponin value range at each time point in Study C4591007

Dose number/ Sampling time point	Troponin value range (ng/L)	5 to <12 years				12 to <16 years	
		BNT162b2		Placebo		BNT162b2	
		N	n (%) (95% CI)	N	n (%) (95% CI)	N	n (%) (95% CI)
1/Prevax	<3.5	516	495 (95.9) (93.8, 97.5)	257	250 (97.3) (94.5, 98.9)	486	467 (96.1) (94.0, 97.6)
	3.5–9		16 (3.1) (1.8, 5.0)		5 (1.9) (0.6, 4.5)		13 (2.7) (1.4, 4.5)
	>9		5 (1.0) (0.3, 2.2)		2 (0.8) (0.1, 2.8)		6 (1.2) (0.5, 2.7)
2/Day 4	<3.5	503	486 (96.6) (94.6, 98.0)	67	67 (100) (94.6, 100)	465	437 (94.0) (91.1, 95.9)
	3.5–9		9 (1.8) (0.8, 3.4)		0 (0.0, 5.4)		19 (4.1) (2.5, 6.3)
	>9		8 (1.6) (0.7, 3.1)		0 (0.0) (0.0, 5.4)		9 (1.9) (0.9, 3.6)
3/Day 4	<3.5	412	399 (96.8) (94.7, 98.3)	NA	NA	423	397 (93.9) (91.1, 95.9)
	3.5–9		8 (1.9) (0.8, 3.8)		NA		18 (4.3) (2.5, 6.6)
	>9		5 (1.2) (0.4, 2.8)		NA		8 (1.9) (0.8, 3.7)

NA=not assessed; Prevax=prevaccination.

Exact 95% CIs were determined based on the Clopper and Pearson method.

Supplementary Table 2. Percentages of participants by troponin value range at each time point in C4591031 Substudy B

Sampling time point	Troponin value range (ng/L)	BNT162b2		Placebo	
		N	n (%) (95% CI)	N	n (%) (95% CI)
Prevax	<3.5	1347	1256 (93.2) (91.8, 94.5)	1355	1267 (93.5) (92.1, 94.8)
	3.5–9		64 (4.8) (3.7, 6.0)		57 (4.2) (3.2, 5.4)
	>9		27 (2.0) (1.3, 2.9)		31 (2.3) (1.6, 3.2)
Day 4	<3.5	1353	1267 (93.6) (92.2, 94.9)	1360	1266 (93.1) (91.6, 94.4)
	3.5–9		60 (4.4) (3.4, 5.7)		68 (5.0) (3.9, 6.3)
	>9		26 (1.9) (1.3, 2.8)		26 (1.9) (1.3, 2.8)
Month 1	<3.5	1273	1183 (92.9) (91.4, 94.3)	1276	1193 (93.5) (92.0, 94.8)
	3.5–9		57 (4.5) (3.4, 5.8)		52 (4.1) (3.1, 5.3)
	>9		33 (2.6) (1.8, 3.6)		31 (2.4) (1.7, 3.4)

Prevax=prevaccination.

Exact 95% CIs were determined based on the Clopper and Pearson method.

Supplementary Table 3. Percentages of participants within each troponin I level range by vaccine sequence in C4591031 Substudy B

Dose number/ Sampling time point	Troponin value range (ng/L)	Vaccine sequence			
		Sequence 1 (BNT162b2→Placebo)		Sequence 2 (Placebo→BNT162b2)	
		N	n (%) (95% CI)	N	n (%) (95% CI)
1/Prevax	<3.5	751	690 (91.9) (89.7, 93.7)	730	694 (95.1) (93.2, 96.5)
	3.5–9		41 (5.5) (3.9, 7.3)		24 (3.3) (2.1, 4.9)
	>9		20 (2.7) (1.6, 4.1)		12 (1.6) (0.9, 2.9)
1/4 Days	<3.5	719	667 (92.8) (90.6, 94.6)	693	654 (94.4) (92.4, 96)
	3.5–9		33 (4.6) (3.2, 6.4)		31 (4.5) (3.1, 6.3)
	>9		19 (2.6) (1.6, 4.1)		8 (1.2) (0.5, 2.3)
2/Prevax	<3.5	628	576 (91.7) (89.3, 93.8)	600	570 (95.0) (92.9, 96.6)
	3.5–9		33 (5.3) (3.6, 7.3)		23 (3.8) (2.4, 5.7)
	>9		19 (3.0) (1.8, 4.7)		7 (1.2) (0.5, 2.4)
2/4 Days	<3.5	667	612 (91.8) (89.4, 93.7)	634	600 (94.6) (92.6, 96.3)
	3.5–9		37 (5.5) (3.9, 7.6)		27 (4.3) (2.8, 6.1)
	>9		18 (2.7) (1.6, 4.2)		7 (1.1) (0.4, 2.3)
2/1 Month	<3.5	676	623 (92.2) (89.9, 94.1)	645	607 (94.1) (92.0, 95.8)
	3.5–9		29 (4.3) (2.9, 6.1)		24 (3.7) (2.4, 5.5)
	>9		24 (3.6) (2.3, 5.2)		14 (2.2) (1.2, 3.6)

Prevax=prevaccination.

Exact 2-sided CIs were determined based on the Clopper and Pearson method.